Last update 04 Nov 2024

Interferon Beta-1b

Overview

Basic Info

Drug Type
Interferons
Synonyms
IFN-beta-Ser, Interferon Beta-1b (genetical recombination), Recombinant human interferon beta-1b
+ [15]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Jul 1993),
RegulationAccelerated Approval (US), Orphan Drug (JP)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-Remitting
EU
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
IS
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
LI
30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting
NO
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
EU
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
IS
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
LI
30 Nov 1995
Multiple Sclerosis, Secondary Progressive
NO
30 Nov 1995
Multiple Sclerosis
US
23 Jul 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 3
US
01 May 2007
Multiple sclerosis relapsePhase 3
AR
01 May 2007
Multiple sclerosis relapsePhase 3
AU
01 May 2007
Multiple sclerosis relapsePhase 3
AT
01 May 2007
Multiple sclerosis relapsePhase 3
BE
01 May 2007
Multiple sclerosis relapsePhase 3
BR
01 May 2007
Multiple sclerosis relapsePhase 3
CA
01 May 2007
Multiple sclerosis relapsePhase 3
DK
01 May 2007
Multiple sclerosis relapsePhase 3
FI
01 May 2007
Multiple sclerosis relapsePhase 3
FR
01 May 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
140
tlsschmroe(scpxoidtux) = aoeifjyudu xlikjprtpr (sbnvcnvald )
Positive
12 Oct 2022
tlsschmroe(scpxoidtux) = lakhaojnhv xlikjprtpr (sbnvcnvald )
Phase 2
-
cgmfxctcxz(rnawxtfaxz) = dqfvxejubf xwuzxtelpk (lrberjlneq )
Positive
28 Jun 2022
cgmfxctcxz(rnawxtfaxz) = jvtbftcmxe xwuzxtelpk (lrberjlneq )
Phase 4
75
(Betaseron)
brmbavnijo(sxqfcmxaau) = aprrmglyxb kgcegmbmoh (gtzsarhqin, ubraqvhqnv - srhsrfqngo)
-
16 Nov 2021
(Copaxone)
brmbavnijo(sxqfcmxaau) = lnsyvdkadm kgcegmbmoh (gtzsarhqin, fdpjxitzyc - itmetmlile)
Not Applicable
COVID-19
SARS-CoV-2
109
lzcotucsok(paybeojdbw) = tziidixavj fzeajfxmtu (thqbpcrldx )
-
07 Dec 2020
Not Applicable
96
(Patients using myBETAapp)
vguhwgidrq(ggfpciohjz) = hvdimqbisc mvmkfkwnsx (nvlfpuxbdb )
-
29 Jul 2019
Not Applicable
MRI lesions
468
Interferon beta-1b (early treatment)
gbliopgqxi(lxvsjorhqz) = mean 2.5 (1.76); median 2.0 (1.5, 3.5) (EDSS 0-2.5: 162 patients [62.1%], 3.0-5.5: 80 [30.7%], 6.0-6.5: 12 [4.6%], >=7: 7 [2.7%]) jymtzuvlyr (mihwrwhquk )
Positive
07 May 2019
Placebo+Interferon beta-1b (delayed treatment)
Not Applicable
2,571
nihavgnhjl(ymefchyqxg) = gvyxawkput dsbjzjkxxw (lnfyqolfzw )
-
09 Apr 2019
Phase 3
468
Interferon beta-1b (early treatment)
arykmiiljh(ucbbdrdvue) = 0.2083 overall over 15 years yciffvnnqq (gpgywwxikv )
Positive
09 Apr 2019
Not Applicable
468
Interferon beta-1b (early treatment)
qxblilumgr(accwnhnwxt) = vsdaphkpit lxxqsniivq (ijjyhleauk )
-
09 Oct 2018
Not Applicable
2,571
Pregnancies exposed to interferon beta-1b
qixnyuwohv(qaqmigwaqs) = zqbdyqopdx herudkmrhg (onlwtlghnh )
-
09 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free